Drug intelligence / Profile preview

bevacizumab + ziv-aflibercept

Development stage: Discontinued
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Ophthalmic

Overview

A combination of two anti-VEGF drugs. Bevacizumab is a monoclonal antibody that binds to VEGF-A, preventing it from interacting with VEGF receptors. Ziv-aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor, binding to VEGF-A, VEGF-B, and placental growth factor (PlGF). Ziv-aflibercept has approximately 100-fold higher affinity for VEGF-A compared to bevacizumab.

Brand names: Avastin + Eylea
Other names: bevacizumab + ziv-aflibercept-Panhandle Eye Group, LLP-proliferative diabetic retinopathy

Targets

VEGFB (Vascular endothelial growth factor B)PGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on bevacizumab + ziv-aflibercept.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + ziv-aflibercept.

Explore the full profile